CA Patent

CA2759795C — Method and composition for treating diabetic ketoacidosis

Assigned to Midwestern University Glendale · Expires 2016-11-29 · 9y expired

What this patent protects

Methods of treating diabetic ketoacidosis are disclosed. The methods utilize an endothelin antagonist to treat diabetic ketoacidosis in mammals, including humans.

USPTO Abstract

Methods of treating diabetic ketoacidosis are disclosed. The methods utilize an endothelin antagonist to treat diabetic ketoacidosis in mammals, including humans.

Drugs covered by this patent

atrasentan-hydrochloride (ATRASENTAN HYDROCHLORIDE)

Patent Metadata

Patent number: CA2759795C
Jurisdiction: CA
Classification: —
Expires: 2016-11-29
Drug substance claim: No
Drug product claim: No
Assignee: Midwestern University Glendale
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.